Nasdaq

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...
Nasdaq

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and ...
Mena FN

Rapport Therapeutics To Present New Phase 2 Treatment Follow-Up Data For RAP-219 In Focal Onset Seizures At The 2026 American Academy Of Neurology Annual Meeting

(MENAFN- GlobeNewsWire - Nasdaq) BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the“Company”), a clinical-stage biotechnology company ...
Seeking Alpha

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

--Rapport Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric ...